These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 24396453)
61. pH and redox dual-responsive nanoparticles based on disulfide-containing poly(β-amino ester) for combining chemotherapy and COX-2 inhibitor to overcome drug resistance in breast cancer. Zhang S; Guo N; Wan G; Zhang T; Li C; Wang Y; Wang Y; Liu Y J Nanobiotechnology; 2019 Oct; 17(1):109. PubMed ID: 31623608 [TBL] [Abstract][Full Text] [Related]
62. Low-molecular-weight protamine-modified PLGA nanoparticles for overcoming drug-resistant breast cancer. Wang H; Zhao Y; Wang H; Gong J; He H; Shin MC; Yang VC; Huang Y J Control Release; 2014 Oct; 192():47-56. PubMed ID: 25003794 [TBL] [Abstract][Full Text] [Related]
63. PLGA based particles as "drug reservoir" for antitumor drug delivery: characterization and cytotoxicity studies. Chronopoulou L; Domenici F; Giantulli S; Brasili F; D'Errico C; Tsaouli G; Tortorella E; Bordi F; Morrone S; Palocci C; Silvestri I Colloids Surf B Biointerfaces; 2019 Aug; 180():495-502. PubMed ID: 31103709 [TBL] [Abstract][Full Text] [Related]
64. Poly(vinyl alcohol)-graft-poly(lactide-co-glycolide) nanoparticles for local delivery of paclitaxel for restenosis treatment. Westedt U; Kalinowski M; Wittmar M; Merdan T; Unger F; Fuchs J; Schäller S; Bakowsky U; Kissel T J Control Release; 2007 May; 119(1):41-51. PubMed ID: 17346845 [TBL] [Abstract][Full Text] [Related]
65. Co-delivery of Doxorubicin and D-α-Tocopherol Polyethylene Glycol 1000 Succinate by Magnetic Nanoparticles. Metin E; Mutlu P; Gündüz U Anticancer Agents Med Chem; 2018; 18(8):1138-1147. PubMed ID: 29532763 [TBL] [Abstract][Full Text] [Related]
66. Modified nanoprecipitation method to fabricate DNA-loaded PLGA nanoparticles. Niu X; Zou W; Liu C; Zhang N; Fu C Drug Dev Ind Pharm; 2009 Nov; 35(11):1375-83. PubMed ID: 19832638 [TBL] [Abstract][Full Text] [Related]
67. Parthenolide reverses doxorubicin resistance in human lung carcinoma A549 cells by attenuating NF-κB activation and HSP70 up-regulation. Xin Y; Yin F; Qi S; Shen L; Xu Y; Luo L; Lan L; Yin Z Toxicol Lett; 2013 Aug; 221(2):73-82. PubMed ID: 23792430 [TBL] [Abstract][Full Text] [Related]
68. Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism. Shen J; He Q; Gao Y; Shi J; Li Y Nanoscale; 2011 Oct; 3(10):4314-22. PubMed ID: 21892492 [TBL] [Abstract][Full Text] [Related]
69. Tumor microenvironment-labile polymer-doxorubicin conjugate thermogel combined with docetaxel for in situ synergistic chemotherapy of hepatoma. Zhang Y; Zhang J; Xu W; Xiao G; Ding J; Chen X Acta Biomater; 2018 Sep; 77():63-73. PubMed ID: 30006312 [TBL] [Abstract][Full Text] [Related]
70. Novel nanostructured enoxaparin sodium-PLGA hybrid carriers overcome tumor multidrug resistance of doxorubicin hydrochloride. Wang J; Wu L; Kou L; Xu M; Sun J; Wang Y; Fu Q; Zhang P; He Z Int J Pharm; 2016 Nov; 513(1-2):218-226. PubMed ID: 27628785 [TBL] [Abstract][Full Text] [Related]
71. Bile acid-conjugated chondroitin sulfate A-based nanoparticles for tumor-targeted anticancer drug delivery. Lee JY; Chung SJ; Cho HJ; Kim DD Eur J Pharm Biopharm; 2015 Aug; 94():532-41. PubMed ID: 26149228 [TBL] [Abstract][Full Text] [Related]
72. Rational Design of Multifunctional Polymeric Nanoparticles Based on Poly(l-histidine) and d-α-Vitamin E Succinate for Reversing Tumor Multidrug Resistance. Li Z; Chen Q; Qi Y; Liu Z; Hao T; Sun X; Qiao M; Ma X; Xu T; Zhao X; Yang C; Chen D Biomacromolecules; 2018 Jul; 19(7):2595-2609. PubMed ID: 29618203 [TBL] [Abstract][Full Text] [Related]
73. Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro. Kievit FM; Wang FY; Fang C; Mok H; Wang K; Silber JR; Ellenbogen RG; Zhang M J Control Release; 2011 May; 152(1):76-83. PubMed ID: 21277920 [TBL] [Abstract][Full Text] [Related]
74. Bypassing multidrug resistance in human breast cancer cells with lipid/polymer particle assemblies. Li B; Xu H; Li Z; Yao M; Xie M; Shen H; Shen S; Wang X; Jin Y Int J Nanomedicine; 2012; 7():187-97. PubMed ID: 22275834 [TBL] [Abstract][Full Text] [Related]
75. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Wang H; Zhao Y; Wu Y; Hu YL; Nan K; Nie G; Chen H Biomaterials; 2011 Nov; 32(32):8281-90. PubMed ID: 21807411 [TBL] [Abstract][Full Text] [Related]
76. Preparation, characterisation and in vitro and in vivo evaluation of CD44-targeted chondroitin sulphate-conjugated doxorubicin PLGA nanoparticles. Liu P; Chen N; Yan L; Gao F; Ji D; Zhang S; Zhang L; Li Y; Xiao Y Carbohydr Polym; 2019 Jun; 213():17-26. PubMed ID: 30879657 [TBL] [Abstract][Full Text] [Related]
77. Reversal of doxorubicin resistance in multidrug resistant melanoma cells in vitro and in vivo by dipyridamole. Desai PB; Duan J; Sridhar R; Damle BD Methods Find Exp Clin Pharmacol; 1997 May; 19(4):231-9. PubMed ID: 9228648 [TBL] [Abstract][Full Text] [Related]
78. Surface modification of PLGA nanoparticles with biotinylated chitosan for the sustained in vitro release and the enhanced cytotoxicity of epirubicin. Chen H; Xie LQ; Qin J; Jia Y; Cai X; Nan W; Yang W; Lv F; Zhang QQ Colloids Surf B Biointerfaces; 2016 Feb; 138():1-9. PubMed ID: 26638176 [TBL] [Abstract][Full Text] [Related]
79. In vitro and in vivo evaluation of anti-nucleolin-targeted magnetic PLGA nanoparticles loaded with doxorubicin as a theranostic agent for enhanced targeted cancer imaging and therapy. Mosafer J; Abnous K; Tafaghodi M; Mokhtarzadeh A; Ramezani M Eur J Pharm Biopharm; 2017 Apr; 113():60-74. PubMed ID: 28012991 [TBL] [Abstract][Full Text] [Related]
80. Co-delivery of rapamycin- and piperine-loaded polymeric nanoparticles for breast cancer treatment. Katiyar SS; Muntimadugu E; Rafeeqi TA; Domb AJ; Khan W Drug Deliv; 2016 Sep; 23(7):2608-2616. PubMed ID: 26036652 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]